Browsing by Subject "Empagliflozin"
Now showing items 1-6 of 6
-
Comparative efficacy of empagliflozin versus placebo in the treatment of type 1 diabetes mellitus: A meta-analysis of randomized controlled trials
( Uniwersytet Medyczny w Lublinie , 2021 , Article)The objective of this meta-analysis study was to evaluate the comparative efficacy of empagliflozin (25 mg) with placebo in the treatment and management of type 1 diabetes mellitus. This study is a meta-analysis, so an ... -
Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression
( Springer , 2022 , Article)Diabetes mellitus (DM)-induced cardiac morbidities have been the leading cause of death among diabetic patients. Recently, sodium-glucose cotransporter-2 (SGLT-2) inhibitors including empagliflozin (EMPA), which have been ... -
First-line Treatment with Empagliflozin and Metformin Combination Versus Standard Care for Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease in Qatar. A Cost-Effectiveness Analysis
( Elsevier , 2022 , Article)Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown to reduce cardiovascular events and mortality in patients with type 2 diabetes mellitus (T2DM), but they are currently not used as first-line therapy in clinical ... -
Trends of use of SGLT2 inhibitors in Qatar
( Qatar University Press , 2021 , Poster)Background: Type 2 diabetes mellitus (T2DM) represents a growing health challenge in Qatar and worldwide. T2DM is associated with a high risk of cardiovascular (CV) morbidity and mortality, and progression of renal disease. ... -
Understanding the mechanisms mediating cardio-renal benefit of empagliflozin in type 2 diabetes mellitus
( Elsevier , 2023 , Article)In a recently published, post-hoc analysis of the hallmark EMPA-REG OUTCOME trial, Kramer ¨ et al.1 assessed whether changes in cardiac and haemodynamic markers achieved with empagliflozin in subjects with type 2 diabetes ... -
Use of Animal Models for Investigating Cardioprotective Roles of SGLT2 Inhibitors
( Springer , 2023 , Article Review)Sodium-glucose co-transporter 2 (SGLT2) inhibitors represent one type of new-generation type 2 diabetes (T2DM) drug treatment. The mechanism of action of an SGLT2 inhibitor (SGLT2i) in treating T2DM depends on lowering ...